General Information of Drug Therapeutic Target (DTT) (ID: TTM8FR7)

DTT Name KRAS messenger RNA (KRAS mRNA)
Synonyms c-Ki-ras (mRNA); c-K-ras (mRNA); RASK2 (mRNA); Ki-Ras (mRNA); KRAS2 (mRNA); K-Ras 2 (mRNA); GTPase KRas (mRNA)
Gene Name KRAS
DTT Type
Literature-reported target
[1]
BioChemical Class
mRNA target
UniProt ID
RASK_HUMAN
TTD ID
T35474
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAG
QEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDL
PSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGC
VKIKKCIIM
Function
Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
KEGG Pathway
MAPK signaling pathway (hsa04010 )
ErbB signaling pathway (hsa04012 )
Ras signaling pathway (hsa04014 )
Rap1 signaling pathway (hsa04015 )
Chemokine signaling pathway (hsa04062 )
FoxO signaling pathway (hsa04068 )
Sphingolipid signaling pathway (hsa04071 )
PI3K-Akt signaling pathway (hsa04151 )
Dorso-ventral axis formation (hsa04320 )
Axon guidance (hsa04360 )
VEGF signaling pathway (hsa04370 )
Tight junction (hsa04530 )
Gap junction (hsa04540 )
Signaling pathways regulating pluripotency of stem cells (hsa04550 )
Natural killer cell mediated cytotoxicity (hsa04650 )
T cell receptor signaling pathway (hsa04660 )
B cell receptor signaling pathway (hsa04662 )
Fc epsilon RI signaling pathway (hsa04664 )
Long-term potentiation (hsa04720 )
Neurotrophin signaling pathway (hsa04722 )
Cholinergic synapse (hsa04725 )
Serotonergic synapse (hsa04726 )
Long-term depression (hsa04730 )
Regulation of actin cytoskeleton (hsa04810 )
Insulin signaling pathway (hsa04910 )
GnRH signaling pathway (hsa04912 )
Progesterone-mediated oocyte maturation (hsa04914 )
Estrogen signaling pathway (hsa04915 )
Melanogenesis (hsa04916 )
Prolactin signaling pathway (hsa04917 )
Thyroid hormone signaling pathway (hsa04919 )
Oxytocin signaling pathway (hsa04921 )
Aldosterone-regulated sodium reabsorption (hsa04960 )
Alcoholism (hsa05034 )
Hepatitis C (hsa05160 )
Hepatitis B (hsa05161 )
HTLV-I infection (hsa05166 )
Pathways in cancer (hsa05200 )
Viral carcinogenesis (hsa05203 )
Proteoglycans in cancer (hsa05205 )
MicroRNAs in cancer (hsa05206 )
Colorectal cancer (hsa05210 )
Renal cell carcinoma (hsa05211 )
Pancreatic cancer (hsa05212 )
Endometrial cancer (hsa05213 )
Glioma (hsa05214 )
Prostate cancer (hsa05215 )
Thyroid cancer (hsa05216 )
Melanoma (hsa05218 )
Bladder cancer (hsa05219 )
Chronic myeloid leukemia (hsa05220 )
Acute myeloid leukemia (hsa05221 )
Non-small cell lung cancer (hsa05223 )
Central carbon metabolism in cancer (hsa05230 )
Choline metabolism in cancer (hsa05231 )
Reactome Pathway
Activation of RAS in B cells (R-HSA-1169092 )
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants (R-HSA-1236382 )
SHC1 events in ERBB2 signaling (R-HSA-1250196 )
SHC1 events in ERBB4 signaling (R-HSA-1250347 )
p38MAPK events (R-HSA-171007 )
GRB2 events in EGFR signaling (R-HSA-179812 )
SHC1 events in EGFR signaling (R-HSA-180336 )
GRB2 events in ERBB2 signaling (R-HSA-1963640 )
Tie2 Signaling (R-HSA-210993 )
EGFR Transactivation by Gastrin (R-HSA-2179392 )
DAP12 signaling (R-HSA-2424491 )
SHC-related events triggered by IGF1R (R-HSA-2428933 )
FCERI mediated MAPK activation (R-HSA-2871796 )
NCAM signaling for neurite out-growth (R-HSA-375165 )
VEGFR2 mediated cell proliferation (R-HSA-5218921 )
CD209 (DC-SIGN) signaling (R-HSA-5621575 )
Constitutive Signaling by EGFRvIII (R-HSA-5637810 )
SHC-mediated cascade (R-HSA-5654688 )
FRS-mediated FGFR1 signaling (R-HSA-5654693 )
SHC-mediated cascade (R-HSA-5654699 )
FRS-mediated FGFR2 signaling (R-HSA-5654700 )
SHC-mediated cascade (R-HSA-5654704 )
FRS-mediated FGFR3 signaling (R-HSA-5654706 )
FRS-mediated FGFR4 signaling (R-HSA-5654712 )
SHC-mediated cascade (R-HSA-5654719 )
Regulation of RAS by GAPs (R-HSA-5658442 )
RAF activation (R-HSA-5673000 )
RAF/MAP kinase cascade (R-HSA-5673001 )
MAP2K and MAPK activation (R-HSA-5674135 )
Negative regulation of MAPK pathway (R-HSA-5675221 )
Insulin receptor signalling cascade (R-HSA-74751 )
SOS-mediated signalling (R-HSA-112412 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
4 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS 6957 DMTHO4A Discovery agent N.A. Investigative [2]
ISIS 6958 DM83EK9 Discovery agent N.A. Investigative [3]
ISIS 7453 DMOX7FJ Discovery agent N.A. Investigative [3]
PNT-300 DM8WJQ0 Solid tumour/cancer 2A00-2F9Z Investigative [1]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2824).
2 Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem. 1996 Nov 8;271(45):28259-65.
3 US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.